The Beauty Health Company’s (NASDAQ:SKIN – Get Rating) stock has been assigned an average “medium buy” recommendation from the eight rating agencies that currently cover the company, MarketBeat reports. I’m here. One analyst rated the stock with a Hold rating and four gave the company a Buy rating. His average 12-month price target for analysts who updated their coverage on the stock last year is his $20.00.
SKIN is the topic of several analyst reports. DA Davidson raised Beauty Health’s price target to his $32.00 in a research report on Tuesday, Nov. 15. Goldman Sachs Group lowered its price target for Beauty Health from $22.00 to $19.00 and gave the stock a ‘buy’ rating in a research report on Wednesday, Nov. 23. Piper Sandler lowered Beauty Health’s target price to $15.00 from her $16.00 in a research report on Friday, Dec. 16. Finally, JP Morgan Chase & Co. downgraded Beauty Health’s rating from ‘overweight’ to ‘neutral’ and lowered the company’s price target from $22.00 to $11.00 in a research report on Wednesday, November 9. I was.
Institutional investors focus on beauty and health
Hedge funds have recently changed their stock positions. Nisa Investment Advisors LLC raised his stake in Beauty Health by 88.9% in the third quarter. Nisa Investment Advisors LLC now owns 4,490 shares of the company worth $52,000 after purchasing an additional 2,113 of his shares during the previous quarter. Point72 Hong Kong Ltd purchased a new stake in Beauty Health for approximately $85,000 in the third quarter. The Royal Bank of Canada increased its shares of Beauty Health by 22.8% in the third quarter. Royal Bank of Canada now owns 7,700 of his shares worth $91,000 after purchasing an additional 1,430 of his shares last quarter. Amundi bought a new stake in Beauty Health in the second quarter for around $92,000. Finally, Ensign Peak Advisors Inc purchased new shares of Beauty Health in the second quarter for approximately $107,000. 78.37% of the shares are currently owned by hedge funds and other institutional investors.
Beauty health stocks down 1.2%
SKIN shares opened at $9.10 on Monday. The stock has a market cap of $1.3 billion, a price/earnings ratio of -27.58, and a beta of 0.97. His one-year low in Beauty Health is $8.25 and his one-year high is $24.77. His 50-day simple moving average for this business is $10.28 and his 200-day simple moving average is $11.78. The company has a debt to equity ratio of 2.84, a current ratio of 11.68 and a quick ratio of 10.34.
Beauty Health (NASDAQ:SKIN – Get Rating) last reported results on Tuesday, November 8th. The company reported earnings of $0.02 per share for his quarter, meeting consensus expectations of $0.02. The company posted revenue of $88.79 million for the quarter, compared to consensus expectations of $80.41 million. Beauty Health had a return on equity of 1.06% and a net profit margin of 6.73%. For the group as a whole, equity analysts expect Beauty Health to post earnings per share of 0.26 for the current financial year.
About Beauty Health
The Beauty Health Company designs, develops, manufactures, markets and distributes aesthetic technologies and products worldwide. The company’s flagship products include HydraFacial, which cleanses, exfoliates, exfoliates, extracts, infuses and moisturizes skin with proprietary solutions and serums.
This instant news alert was generated by Narrative Science Technology and MarketBeat financial data to provide our readers with the fastest and most accurate reporting. This article was reviewed by MarketBeat’s editorial team prior to publication. Send any questions or comments about this story to email@example.com.
Before you think about beauty health, I would love to hear from you.
MarketBeat tracks Wall Street’s most acclaimed and top performing research analysts and the stocks they recommend to clients every day. MarketBeat identified five stocks top analysts are quietly whispering to clients to buy now before the broader market catches on…and Beauty Health wasn’t on the list. .
Beauty Health currently holds a ‘moderate buy’ rating among analysts, although the highest rated analysts believe these five stocks are better buys.
See 5 stocks here